argenx (ARGX) Q3 2026 Earnings Call Transcript

Wells Fargo lowered Argenx's price target to $1,336 from $1,356, maintaining an Overweight rating. The firm expects positive December data to drive a re-rating. CoreWeave shares fell 1% after a 10% drop, while Nokia rose 4.5% on strong AI-related sales. CoreWeave faces financing concerns, while Nokia shows AI growth.

Baird raised its price target for argenx SE (NASDAQ:ARGX) to $861, citing strong Vyvgart sales of $1.72B in Q3 2026, beating estimates. The company reported 70% revenue growth and profitability. Multiple analysts maintain Buy ratings with varying targets, noting sector challenges and upcoming data.

argenx SE (ARGNF) reported a 54% surge in VYVGART sales. The company increased 2026 OpEx guidance to $4B, with half attributed to the Forte acquisition. Management expects growth in MG and CIDP revenues, with additional indications driving Vision 2030. Potential 2027 launches include MMN, pending positive IMPASSION data. The FDA requested an additional dermatomyositis trial, and management remains confident in delivering Vision 2030.

argenx SE reported Q3 2026 product net sales of $1.7B, up 54% YoY. VYVGART's seronegative MG launch saw strong access. Phase 3 ALKIVIA results support autoimmune myositis expansion. Operating expenses are rising to $4B, up 45% YoY, due to acquisitions and pipeline investments. The FDA required an additional trial for dermatomyositis, delaying approval. Empasiprubart's Phase 3 study in MMN is expected in December. The company did not provide formal revenue guidance, citing uncertainty.

Jefferies reiterated a Buy rating and $1,200 price target for argenx SE (ARGX) after its Q3 results. The company reported Vyvgart revenues of $1.7B, a 5% beat, and EPS of $7.80, in line with estimates. Operating expenses were higher due to the Forte deal. Analysts expect data readouts and revenue growth to drive future performance, with projections of $6.5B in FY2026 revenues. Other analysts have mixed price target adjustments.

argenx (ARGX) reported Q3 earnings, highlighting growth in VYVGART sales for MG and CIDP. The company expanded seronegative label coverage and submitted applications for pediatric and ocular MG. It plans up to five U.S. launches in 2027, including potential MG label expansions, IMNM, an auto-injector, and a possible MMN launch for empasiprubart. Pipeline updates include positive Phase II results for FB-102 in celiac disease and advancements in other programs.